# Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

> **NCT02916771** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 61 (actual)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02916771
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-01-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02916771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02916771, "Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02916771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*